EUVIMEDEUVIMED entdecken
Übersichtsarbeit

High-Dose Methotrexate Nephrotoxicity

Jaya Kala, Scott C Howard

American Journal of Nephrology · 2025

DOI: 10.1159/000549144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Nephrology, 2025. Verfasst von Jaya Kala und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University of Texas Health Science Center-McGovern Medical School, Houston, Texas, USA, jaya…. Hauptthemen laut MEDLINE: Methotrexate, Acute Kidney Injury, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Methotrexate (MTX) is an antimetabolite anticancer agent that has been used at doses ranging from 20 mg/m2 of body surface area to 33,000 mg/m2. High-dose methotrexate (HDMTX), defined as doses higher than 500 mg/m2, is used to treat acute lymphoblastic leukemia, non-Hodgkin lymphoma, osteosarcoma, brain cancers, leptomeningeal spread of carcinomas, and other cancers. Depending on the dose and other factors, acute kidney injury occurs in 2%–39% of HDMTX courses and severe (Acute Kidney Injury Network grade 2 or higher) nephrotoxicity in approximately 2%, though incidence varies widely. Prompt recognition and treatment of delayed MTX elimination and renal dysfunction which includes increased hydration, high-dose leucovorin, and sometimes glucarpidase, is crucial to prevent life-threatening toxicities such as myelosuppression, mucositis, renal failure, and dermatitis. Summary: In this article, we emphasize the importance of MTX pharmacokinetics and pharmacodynamics, highlight the cellular mechanisms of MTX anticancer activity, review the pathophysiology of MTX-induced renal injury, and explore strategies to prevent and manage MTX nephrotoxicity. Key Messages: Prompt recognition and effective treatment of renal and non-renal toxicities of HDMTX can improve outcomes, cancer prognosis, and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateAcute Kidney InjuryAntimetabolites, AntineoplasticHumansLeucovorinDose-Response Relationship, DrugNeoplasmsgamma-Glutamyl HydrolaseRecombinant Proteins

Stichwörter der Autor:innen

Acute kidney injuryChemotherapyHigh-dose methotrexateLeucovoringlucarpidase

Substanzen

MethotrexateAntimetabolites, AntineoplasticLeucovoringlucarpidasegamma-Glutamyl HydrolaseRecombinant Proteins

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, University of Texas Health Science Center-McGovern Medical School, Houston, Texas, USA, jaya.kala@uth.tmc.edu.
  • Sant Joan de Deu Hospital, Barcelona, Spain.
  • Yeolyan Hematology-Oncology Center, Yerevan, Armenia.
  • Resonance, Memphis, Tennessee, USA.

Zitieren

APA

Kala, J., & Howard, S. C. (2025). High-Dose Methotrexate Nephrotoxicity. American Journal of Nephrology. https://doi.org/10.1159/000549144

Vancouver

Kala J, Howard SC. High-Dose Methotrexate Nephrotoxicity. American Journal of Nephrology. 2025. doi:10.1159/000549144

BibTeX
@article{Kala2025,
  author = {Kala, Jaya and Howard, Scott C},
  title = {High-Dose Methotrexate Nephrotoxicity},
  journal = {American Journal of Nephrology},
  year = {2025},
  doi = {10.1159/000549144}
}
Kostenlos starten →